In a recent paper from the group of Dr. Joyce, the TME of both patients with primary (GBM) or metastatic brain tumors was interrogated at the single-cell level; the analysis revealed similarities and differences in T cell phenotype and function, with the most pronounced differences observed in the relative abundance of CD39+ potentially tumor-reactive T cells [40]. The gene discussed is ENTPD1; the disease is neoplasm.